Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Shenzhen - Delayed Quote CNY

PharmaResources (Shanghai) Co., Ltd. (301230.SZ)

26.71
-1.54
(-5.45%)
At close: 3:04:55 PM GMT+8
Loading Chart for 301230.SZ
  • Previous Close 28.25
  • Open 29.78
  • Bid 26.73 x --
  • Ask 26.76 x --
  • Day's Range 26.50 - 27.50
  • 52 Week Range 18.41 - 45.40
  • Volume 8,997,906
  • Avg. Volume 7,616,954
  • Market Cap (intraday) 3.728B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) 222.58
  • EPS (TTM) 0.12
  • Earnings Date --
  • Forward Dividend & Yield 0.43 (1.52%)
  • Ex-Dividend Date Oct 24, 2024
  • 1y Target Est --

PharmaResources (Shanghai) Co., Ltd. operates as a CRO, CDMO, and CMO service provider of drug discovery in China. It also manufactures APIs and key intermediates. The company offers preclinical services. In addition, the company manufactures small molecule related medicine. PharmaResources (Shanghai) Co., Ltd. was founded in 2007 and is based in Shanghai, China.

www.pharmaresources.cn

--

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 301230.SZ

View More

Performance Overview: 301230.SZ

Trailing total returns as of 4/28/2025, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

301230.SZ
4.66%
SSE Composite Index (000001.SS)
1.89%

1-Year Return

301230.SZ
4.91%
SSE Composite Index (000001.SS)
6.47%

3-Year Return

301230.SZ
1.28%
SSE Composite Index (000001.SS)
10.52%

5-Year Return

301230.SZ
1.28%
SSE Composite Index (000001.SS)
17.02%

Compare To: 301230.SZ

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 301230.SZ

View More

Valuation Measures

Annual
As of 4/28/2025
  • Market Cap

    3.73B

  • Enterprise Value

    3.57B

  • Trailing P/E

    222.58

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    6.98

  • Price/Book (mrq)

    3.61

  • Enterprise Value/Revenue

    6.56

  • Enterprise Value/EBITDA

    57.75

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    3.14%

  • Return on Assets (ttm)

    -0.14%

  • Return on Equity (ttm)

    1.59%

  • Revenue (ttm)

    544.47M

  • Net Income Avi to Common (ttm)

    17.08M

  • Diluted EPS (ttm)

    0.12

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    336.29M

  • Total Debt/Equity (mrq)

    17.59%

  • Levered Free Cash Flow (ttm)

    -132.04M

Research Analysis: 301230.SZ

View More

Company Insights: 301230.SZ

Research Reports: 301230.SZ

View More